Search

Your search keyword '"Erickson, Stephen"' showing total 1,062 results

Search Constraints

Start Over You searched for: Author "Erickson, Stephen" Remove constraint Author: "Erickson, Stephen"
1,062 results on '"Erickson, Stephen"'

Search Results

53. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

54. Congophilic Fibrillary Glomerulonephritis: A Case Series

58. Empirical Bayes estimation of a sparse vector of gene expression changes

59. Transforming Diagnosis and Treatment of Pediatric Pneumonia Through Point-Of-Care Lung Ultrasound

60. Higher severe acute respiratory syndrome coronavirus 2 infection rate in pregnant patients

61. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State

63. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts

67. Development of a Replication-Deficient Bacteriophage Reporter Lacking an Essential Baseplate Wedge Subunit.

68. Figures S1-7 from Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

69. Data from Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

70. Data from ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium

71. Supplementary Figure from Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

72. Supplementary Data from ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium

73. Supplementary Data from The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

74. Supplementary Supplementary Methods, Supplementary Tables 1-6, Supplementary Figures 1-9 from Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

75. Supplementary Data from OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

82. Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

83. MAC Plus Study: A Retrospective Study Correlating DNA Variants, Clinical Course and Outcomes from 187 Patients Who Underwent Testing Using an Atypical Hemolytic Uremic Syndrome and Thrombotic Microangiopathy Genetic Sequencing Panel

84. Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia

89. No Longer, Not Yet

92. Introduction

94. Reconstruction of a Nasal Tip Defect.

96. Family Life, Bioethics and Confucianism

100. Evaluation of the pan‐class I phosphoinositide 3‐kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma

Catalog

Books, media, physical & digital resources